{"id":956998,"date":"2026-04-30T18:42:06","date_gmt":"2026-04-30T22:42:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/"},"modified":"2026-04-30T18:42:06","modified_gmt":"2026-04-30T22:42:06","slug":"reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/","title":{"rendered":"REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026"},"content":{"rendered":"
\n

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) — Kirby McInerney LLP<\/a> reminds Aldeyra Therapeutics, Inc. (\u201cAldeyra\u201d or the \u201cCompany\u201d) (NASDAQ:ALDX) investors of the May 29, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.<\/p>\n

If you purchased or otherwise acquired Aldeyra securities, have information, or would like to learn more, please contact Lauren Molinaro<\/a> of Kirby McInerney LLP by email at investigations@kmllp.com<\/a>, or fill out the form below, to discuss your rights or interests.<\/p>\n

[CONTACT THE FIRM IF YOU SUFFERED A LOSS<\/a>]<\/p>\n

\n What Is The Lawsuit About?<\/strong>\n <\/p>\n

The lawsuit has been filed on behalf of investors who purchased securities during the period of November 3, 2023 through March 16, 2026, inclusive (\u201cthe Class Period\u201d). The lawsuit alleges that Aldeyra failed to disclose that (1) the results of the reproxalap (an Aldeyra drug candidate) clinical trials were inconsistent; and (2) the inconsistency of the results rendered any purported positive findings from these trials unreliable and not meaningful.<\/p>\n

On March 17, 2026, the Company filed with the SEC a current report on Form 8-K, announcing receipt of a Complete Response Letter from the FDA, stating that there is \u201ca lack of substantial evidence consisting of adequate and well-controlled investigations \u2026 that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling\u201d and that \u201cthe application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.\u201d The Complete Response Letter also stated that the \u201cinconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings\u201d and that \u201cthe totality of evidence from the completed clinical trials does not support the effectiveness of the product.\u201d\u00a0On this news, the price of Aldeyra shares declined by $2.99 per share, or approximately 71%, from $4.23 per share on March 16, 2026 to close at $1.24 on March 17, 2026.<\/p>\n

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION<\/a>]<\/p>\n

\n What Should I Do?<\/strong>\n <\/p>\n

If you purchased or otherwise acquired Aldeyra securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro<\/a> of Kirby McInerney LLP<\/a> by email at investigations@kmllp.com<\/a>, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.<\/p>\n

[WHAT IS A SECURITIES CLASS ACTION?<\/a>]<\/p>\n

\n Kirby McInerney LLP<\/a> is a New York-based plaintiffs\u2019 law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm\u2019s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP\u2019s website<\/a>.<\/p>\n

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n

Contacts
Kirby McInerney LLP\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Lauren Molinaro, Esq.
212-699-1171
https:\/\/www.kmllp.com<\/a>
https:\/\/securitiesleadplaintiff.com\/<\/a>
investigations@kmllp.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) — Kirby McInerney LLP reminds Aldeyra Therapeutics, Inc. (\u201cAldeyra\u201d or the \u201cCompany\u201d) (NASDAQ:ALDX) investors of the May 29, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. If you purchased or otherwise acquired Aldeyra securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your rights … <\/p>\n

Continue reading “REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-956998","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nREMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) — Kirby McInerney LLP reminds Aldeyra Therapeutics, Inc. (\u201cAldeyra\u201d or the \u201cCompany\u201d) (NASDAQ:ALDX) investors of the May 29, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. If you purchased or otherwise acquired Aldeyra securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your rights … Continue reading "REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T22:42:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTEzOSM3NTc3NTgyIzIwMjA2Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026\",\"datePublished\":\"2026-04-30T22:42:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\\\/\"},\"wordCount\":529,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMTEzOSM3NTc3NTgyIzIwMjA2Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\\\/\",\"name\":\"REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMTEzOSM3NTc3NTgyIzIwMjA2Njk=\",\"datePublished\":\"2026-04-30T22:42:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMTEzOSM3NTc3NTgyIzIwMjA2Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMTEzOSM3NTc3NTgyIzIwMjA2Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/","og_locale":"en_US","og_type":"article","og_title":"REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026 - Market Newsdesk","og_description":"NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) — Kirby McInerney LLP reminds Aldeyra Therapeutics, Inc. (\u201cAldeyra\u201d or the \u201cCompany\u201d) (NASDAQ:ALDX) investors of the May 29, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. If you purchased or otherwise acquired Aldeyra securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your rights … Continue reading \"REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-30T22:42:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTEzOSM3NTc3NTgyIzIwMjA2Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026","datePublished":"2026-04-30T22:42:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/"},"wordCount":529,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTEzOSM3NTc3NTgyIzIwMjA2Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/","name":"REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTEzOSM3NTc3NTgyIzIwMjA2Njk=","datePublished":"2026-04-30T22:42:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTEzOSM3NTc3NTgyIzIwMjA2Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTEzOSM3NTc3NTgyIzIwMjA2Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-aldeyra-therapeutics-inc-investors-with-significant-losses-must-act-by-may-29-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/956998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=956998"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/956998\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=956998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=956998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=956998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}